3Q'25 vs. 3Q'24 Results NII: € 375 M (-2.3% vs. -2% BS(e) and -3.3% consensus); Total Revenues: € 515 M (+0.2% vs. +0.2% BS(e) and -0.5% consensus); Operating Income: € 276 M (-3.5% vs. -3.6% BS(e) and -4.9% consensus); Net Profit: € 165 M (+5.4% vs. +1.3% BS(e) and -4.8% consensus); 3Q'25 vs.. 2Q'25 Results NII: € 375 M (+0.3% vs. +0.6% BS(e) and -0.8% consensus); Total Revenues: € 515 M (-5.2% vs. -+5.2% BS(e) and -5.9% consensus); Operating Income: € 276 M (-9.9% vs. -10% BS(e) and -11.2% con...
3Q'25 vs. 3Q'24 Results NII: € 2.67 Bn (-4.3% vs.. -5.3% BS(e) and -4.7% consensus); Total Revenues: € 4.08 Bn (-0.4% vs. -1.9% BS(e) and -1.5% consensus); Operating Income: 2.46 Bn (-3.9% vs. -5.8% BS(e) and -5.3% consensus); Net Profit pre AT1: € 1.4 Bn (-8.1% vs. -4.4% BS(e) and -9.7% consensus). 3Q'25 vs.. 2Q'25 Results NII: € 2.67 Bn (+1.4% vs. +0.3% BS(e) and +1% consensus); Total Revenues: € 4.08 Bn (+1.2% vs. -0.4% BS(e) and 0% consensus); Operating Income: € 2.46 Bn (+1.1% vs. -0.9% BS(...
3Q'25 vs. 3Q'24 Results Sales: € 616.6 M (+5.6% vs. +4.5% BS(e) and +4.2% consensus); EBITDA: € 192.2 M (+2.1% vs. +2.7% BS(e) and +3.0% consensus); 9M'25 vs. 9M'24 Results Sales: € 1.603 Bn (+3.8% vs. +3.4% BS(e) and +3.3% consensus); EBITDA: € 435.8 M (+1.7% vs. +2.0% BS(e) and +2.1% consensus);
Rdos. 3T'25 vs 3T'24: M. Intereses: 375 M euros (-2,3% vs -2% BS(e) y -3,3% consenso); M. Bruto: 515 M euros (+0,2% vs +0,2% BS(e) y -0,5% consenso); M. Neto: 276 M euros (-3,5% vs -3,6% BS(e) y -4,9% consenso); BDI: 165 M euros (+5,4% vs +1,3% BS(e) y -4,8% consenso); Rdos. 3T'25 vs 2T'25: M. Intereses: 375 M euros (+0,3% vs +0,6% BS(e) y -0,8% consenso); M. Bruto: 515 M euros (-5,2% vs -+5,2% BS(e) y -5,9% consenso); M. Neto: 276 M euros (-9,9% vs -10% BS(e) y -11,2% consenso); BDI: 165 M eur...
Ventas 9meses’25 vs 9meses’24 No Vida: 46.154 M euros (+3,7% vs +4,8% BS(e) y 4,7% consenso); Vida: 27.822 M euros (+10,9% vs +10,0% BS(e) y +7,7% de consenso) Salud: 14.505 M euros (+10,3% vs +10,5% BS(e) y +9,6% consenso); Gestión de activos: 875,0 M euros (-28,4% vs -28,4% BS(e) y -28,4% consenso); Ventas totales: 89.424 M euros (+5,5% vs +5,9% BS(e) y +5,0 consenso).
Rdos. 3T'25 vs 3T'24: Ventas: 616,6 M euros (+5,6% vs +4,5% BS(e) y +4,2% consenso); EBITDA: 192,2 M euros (+2,1% vs +2,7% BS(e) y +3,0% consenso). Rdos. 9meses'25 vs 9meses'24: Ventas: 1.603 M euros (+3,8% vs +3,4% BS(e) y +3,3% consenso); EBITDA: 435,8 M euros (+1,7% vs +2,0% BS(e) y +2,1% consenso).
NEWS SUMMARY: BANKINTER, CAIXABANK, ELECTRICITY SECTOR, MELIÁ, PUIG BRANDS, SANTANDER, UNICAJA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’25 results to be released over the coming days in Spain. Profit taking after Central Bank meetings European stock markets slid amid 3Q’25 results and the Central Banks meetings. In the STOXX 600, Technology and Travel&Leisure were th...
Rdos. 3T'25 vs 3T'24: M. Intereses: 2.674 M euros (-4,3% vs -5,3% BS(e) y -4,7% consenso); M. Bruto: 4.077 M euros (-0,4% vs -1,9% BS(e) y -1,5% consenso); M. Neto: 2.458 M euros (-3,9% vs -5,8% BS(e) y -5,3% consenso); BDI pre AT1: 1.445 M euros (-8,1% vs -4,4% BS(e) y -9,7% consenso). Rdos. 3T'25 vs 2T'25: M. Intereses: 2.674 M euros (+1,4% vs +0,3% BS(e) y +1% consenso); M. Bruto: 4.077 M euros (+1,2% vs -0,4% BS(e) y 0% consenso); M. Neto: 2.458 M euros (+1,1% vs -0,9% BS(e) y -0,4% consens...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CAIXABANK, MELIÁ, SECTOR ELÉCTRICO, PUIG BRANDS, UNICAJA. EUROPA: AXA, BAYER, SECTOR BANCARIO, UNICREDIT. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. Toma de beneficios post Bancos Centrales Las bolsas a ambos lados del Atlántico se decant...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.